[go: up one dir, main page]

WO2001082901A1 - Nouveaux anticorps diriges sur des membranes biologiques - Google Patents

Nouveaux anticorps diriges sur des membranes biologiques Download PDF

Info

Publication number
WO2001082901A1
WO2001082901A1 PCT/US2001/013852 US0113852W WO0182901A1 WO 2001082901 A1 WO2001082901 A1 WO 2001082901A1 US 0113852 W US0113852 W US 0113852W WO 0182901 A1 WO0182901 A1 WO 0182901A1
Authority
WO
WIPO (PCT)
Prior art keywords
membrane
antibody
intracellular membrane
intracellular
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/013852
Other languages
English (en)
Inventor
Charles B. Hensley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zengen Inc
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Priority to US10/258,977 priority Critical patent/US20030211111A1/en
Priority to AU2001262960A priority patent/AU2001262960A1/en
Publication of WO2001082901A1 publication Critical patent/WO2001082901A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Definitions

  • the present invention relates to the field of biological membranes.
  • Biological membranes are important cellular structures that are generally involved in containing, compartmentalizing, and regulating the transfer of metabolites and macromolecules in a living organism.
  • Biological membranes are composed of phospholipid bilayers associated with a range of proteins, carbohydrates, glycoproteins, glycolipids and other lipid molecules such as cholesterol.
  • Different biological membranes have also evolved with specialized functions ranging from energy conversion in mitochondria or chloroplasts, protein production in the endoplasmic reticulum and the golgi complex, to signal or impulse relay in neural membranes.
  • Subcellular organelles and components such as the endoplasmic reticulum, golgi complex, mitochondria, lysosomes, vacuoles, peroxisomes, chloroplast, to name a few, have specialized functions due to certain distinctive characteristics of their membranes. Hence, the ability to identify and target these particular membrane components can be important to further elucidate and to regulate the functions of these membranes or functions associated with them.
  • the present invention is directed toward antibodies specific for particular intracellular membrane components and the method of using these antibodies.
  • injecting isolated membrane components into mice may generate specific antibodies to particular membrane components.
  • the injection may include a membrane component by itself or in combination with another membrane component using an immunosuppression method.
  • these antibodies are used as a novel method and system for drug delivery targeted to particular intracellular membrane components.
  • Another aspect of the invention involves the use of these antibodies for identifying particular intracellular membrane components important for cell functions.
  • the present invention involves antibodies specific for particular intracellular membrane components and the method of using these antibodies.
  • standard fractionation, sedimentation, density-centrifugation, and/or phase- partition techniques may be used to isolate different intracellular membrane components.
  • membrane components include, but are not limited to, the golgi complex, endoplasmic reticulum, mitochondria, nuclear membrane, apical membrane, basal-lateral membrane, lysosomal membrane, secretory vesicles, vacuolar membrane, tubulovesicular membranes, microtubules, and brush borders fragments of intestinal epithelial cells.
  • These components may be isolated from different cells such as hepatocytes, intestinal epithelium, lacrimal cells, cardiomyoctes, proximal tubules, etc. Afterwards, conventional polyclonal or monoclonal antibody production methods can be used to generate antibodies that recognize these particular intracellular membrane components of the cells.
  • an immunosuppression method may enhance the antibody specificity toward one set of membrane components over another set of membrane components.
  • This immunosuppression method uses cyclophosphamide and is described in Carnahan, J. and Patterson, P., The Generation of Monoclonal Antibodies that Bind Preferentially to Adrenal Chromaffin Cells and the Cells of Embryonic Sympathetic Ganglia, J. of Neuroscience. 11(11): 3493-3506. See also Matthew, W. and Patterson, P., Cyclophosphamide treatment used to manipulate the immune response for the production of monoclonal antibodies. J. Immunol. Methods, 100:73-82 (1987).
  • co-injecting cyclophosphamide with an endoplasmic reticulum fraction may desensitize or make the mice immunotolerant to particular antigens represented in the endoplasmic reticulum.
  • injecting the mice with a golgi complex fraction without cyclophosphamide may preferentially immunize the mice to certain antigens represented in the golgi complex but not in the endoplasmic reticulum. This may then generate antibodies that preferentially recognize antigens in the golgi complex, but not in the endoplasmic reticulum.
  • these antibodies may be used as a novel method and system for drug delivery, hi a preferred embodiment of the invention, carriers of a therapeutic agent are coupled to the antibodies generated and directed to particular intracellular membrane components of the cells. These antibodies act as targeting or homing agents that specifically deliver the therapeutic agents to the particular intracellular membrane components.
  • the carriers can include immuno liposomes wherein the antibody or part of the antibody such as the Fab portion or a single chain of the antibody, is covalently coupled to liposomes. Park J.W., et. al., Anti-HER2 Immunoliposomes for Targeted Therapy of Human Tumors, Cancer Lett. 118(2): 153-60 (1997).
  • the immunoliposomes can also include two different set of antibodies; one set of the antibodies is directed toward extracellular antigens that identify specific cells and the other set is directed toward the intracellular components of the identified cells. Thus, these immunoliposomes can first target certain cells, carry the therapeutic agent into these cells, and further home in on certain intracellular components for the therapeutic agent to act upon.
  • the antibody or part of the antibody for specific intracellular components can also be directly conjugated or covalently attached to the therapeutic agent.
  • Injections into specific tissues such as the muscles or skin deliver the drug-modified antibody locally, and the cells can take up this drug-modified antibody by endocytosis or pinocytosis.
  • To increase the uptake of the drug-modified antibody it may further be modified by techniques such as cationization, as described in Pardridge, W.M., et. al., Enhanced Cellular Uptake and in vivo Biodistribution of a Monoclonal Antibody Following Cationization, J, Pharm. Sci., 84(8):943-8 (1995).
  • the drug-modified antibody may also be delivered locally to a specific tissue using an implantable pump or encapsulating it in a biodegradable slow-release capsule.
  • the therapeutic agent can include various different molecules ranging from enzymes, proteins, chemicals, inhibitors, radiolabels, nucleic acids, carbohydrate moieties, etc. Numerous techniques can be used to attach these molecules to the antibody, and they are listed and described in U.S. Patent Nos. 5,194,594, 5990,286, and 6,017,514, which are incorporated herein by reference.
  • these antibodies for use in drug deliveries may be humanized using techniques described in U.S. Patent No. 5,866,692 entitled “Process for Producing Humanized Chimera Antibody,” which is incorporated herein by reference. Humanization of antibodies decreases the human immune response against foreign antibodies, and thus, increases the effectiveness of these antibodies in human therapy.
  • Another aspect of the invention involves the use of these antibodies to aid in elucidating the functions and properties of different membrane components.
  • These antibodies may be used as diagnostic tools to detect changes in the membrane properties in response to different cellular conditions such as apoptosis, cell division, cell resting and acquiescence, or different systemic conditions of the body such as fever, infections, inflammation, or other diseases.
  • Example I This example illustrates the isolation, fractionation, and identification of different intracellular components. Isolation and purification of these membrane components are described in the following references and are incorporated herein by reference: Bradley, M.E., et. al., Isolation and Identification of Plasma Membrane Populations, Methods in Enzymologv, 228:432-448 (1994); Mircheff, A.K., Isolation of Plasma Membranes from Polar Cells and Tissues: Apical/ Basolateral Separation, Purity, Function, Methods in Enzymologv, 172:18-34 (1989); Mircheff, A.K.
  • the isolation buffer preferably consists of 5% (w/v) sorbitol, 0.5 mM naEDTA, 5 mM histidine-imidazole, pH 7.5, 9 ⁇ g/ml aprotinin, and 0.2 mM PMSF as protease inhibitor.
  • the resulting homogenate may be centrifuged at 2,000g for 10 minutes and the supernatant is saved. To increase yield, the pellet may be re-homogenized and centrifuged while pooling the resulting supematants.
  • the pooled supematants may be centrifuged in a sucrose or sorbitol density gradient either designed as a continuous gradient or a stepwise gradient. For example, four milliliter aliquots of the supematants may be first mixed with six milliliters of 87.4% sorbitol and equilibrated at 4°C for one hour. The samples may be loaded at the junction between two hyperbolic sorbitol gradients ranging between 35 and 70% sorbitol as described in Hensley C.B. et. al., Parathryroid hormone induced translocation ofNa-H antiporters in rat proximal tubules, Am. J. Phvsiol.
  • the gradient solutions may contain 0.5 mM disodium EDTA, 0.2mM PMSF, 9 ⁇ g/ml aprotinin, and 5 mM histidine-imidazole buffer (pH 7.5), and may be centrifuged in a swinging-bucket rotor at 100,000g for five hours. Three-milliliter fractions may then be collected from the top using a Buchler AutoDensi-Flow and may be diluted if necessary. See Zhang, Y., et. al., Rapid distribution and inhibition of renal sodium transporters during acute pressure natriuresis, Am. J. Physiol. 270(6 Part 2): F1004-14 (1996).
  • a subfractionation step such as phase partitioning using thin-layer apparatus, electrophoresis, or density pertubation with digitonin may further differentiate the different membrane components.
  • the phase partitioning may utilize a two phase system consisting of 5% Dextran T-500, 3.5% polyethyleneglycol (Carbowax) 6000, 10 ⁇ m NaEDTA, and 8.3 mM imidazole, adjusted to pH 6.6. or 7.6 with HC1.
  • Fractions of interest from the density gradient isolation may be loaded in the thin-layer apparatus' chambers and suspended in the upper phase at a protein concentration of 1.2 mg protein/ml.
  • the thin-layer apparatus preferably includes a fraction collector ring that holds plastic culture tubes for collecting the resulting fractions.
  • biochemical markers such as enzymes that tend to localize predominantly in certain membranes.
  • these enzymes include: Na + , K + -ATPase that is principally located in basolateral membranes; sucrase and maltase that are principally located in brush border membranes; alkaline phosphatase and ⁇ -Glutamyltransferase that are principally located in apical membranes; galactosyltransferase that is principally located in the trans- golgi elements; N-acetyl- ⁇ -D-glucosaminidase that are principally located in the lysosomes; NADPH-cytochrome-c reductase that are principally located in the endoplasmic reticulum; and succinate dehydrogenase that is principally located in the mitochondria.
  • This example illustrates the immunization of mice with the isolated intracellular components.
  • Intracellular membrane components at about lOO ⁇ g of membrane protein in 500 ⁇ l of PBS containing 25mM EDTA and 3mM PMSF as protease inhibitor may be injected in RBF/m or Balb/c mice.
  • the injection schedule may be performed as follows: day 1: intraperitional injection of one set of intracellular membrane component (set A) with cyclophosphamide at 120mg/kg; day 2: intraperitional injection of cyclophosphamide only at 120mg/kg; day 3: repeat intraperitional injection of cyclophosphamide only at 120mg/kg; day 22: intraperitional injection of a second set of intracellular membrane component (set B), in Complete Freund's Adjuvant; day 40: intravenous injection of the set B in PBS through the tail of the mouse; day 43: the mice may be sacrificed, and their spleen cells isolated and fused using
  • the immunization may be performed without the immunosuppression method outlined from day 1-3.
  • the immunization may start with only one set of intracellular membrane component at day 22 to day 43.
  • a standard dot blot may be performed. Briefly, one ⁇ l of the supernatant from each hybridoma cell line may be applied and dried onto a nitrocellulose or nylon membrane.
  • the nitrocellulose or nylon membrane may then be blocked and incubated with 10% normal goat semm in PBS for one hour to reduce non-specific binding of the secondary antibody.
  • a goat anti-mouse IgG conjugated with horseradish peroxidase may be applied for one hour at an appropriate dilution in PBS containing 2% normal goat serum.
  • the membranes may be washed two to three times with PBS containing 2% normal goat serum.
  • the peroxidase may be incubated with standard ECL chemiluminescence substrate available from Amersham Pharmacia Biotech, Piscataway, New Jersey.
  • Example III This example illustrates the screening of antibodies that recognize the different intracellular membrane components.
  • Nitrocellulose or nylon membranes are cut into a number of longitudinal strips, and different intracellular membrane components isolated above are spotted or applied and dried onto each strip. Blocking may be performed using casein, bovine serum albumin, or normal goat serum in PBS. Supernatant from antibody-producing hybridoma cell lines or serum from immunized mice may or may not be diluted and applied to each strip containing the different intracellular membrane components. Washing may be performed two to three times with PBS containing 2% normal goat serum, and the rest of the reaction may be performed as described in Example II above. Alternatively, the different intracellular membrane components may be applied to a
  • Example IN This example illustrates the verification of antibody specificity using immunohistochemistry.
  • Epithelial cells can be cultured to 80% confluent in Titek eight well glass chamber slides coated with appropriate matrix such as poly-lysine. The cells are then washed with IX PBS and fixed with ice cold 4% paraformaldehyde. To allow access of the antibody to the intracellular components, the cell membranes may be permeabilized with 1% ⁇ P-40 or Triton-X in Tris-HCl Buffered Saline solution pH 7.4 (TBS). The antibody to be tested may be diluted appropriately in TBS and incubated for 1-2 hours at room temperature. The cells may be washed three times with TBS with 0.1% Triton X at fifteen minutes intervals.
  • a secondary antibody specific to mouse IgG molecule with a conjugated fluorescent molecule such as fluorescein and rhodamine can be used to detected where the primary antibody binds. After washing and mounting the slides on suitable medium, the binding of the antibody in the cells can be analyzed under a fluorescence microscope.
  • intracellular binding of the antibodies may be analyzed from whole tissue sections of tissues of interests such as the liver, myocardial tissue, intestinal epithelium, or lacrimal glands. These tissues of interests can be obtained from organ donors or biopsy samples. The tissues are cut into 1-mm cubes and fixed in 4% paraformaldehyde. The tissues may be processed using standard histology techniques and sectioned using a microtome. Antibody labeling may be achieved and analyzed similarly to the cells above.
  • This example illustrates how to verify the specificity of the antibodies using electron microscopy.
  • Tissues of interests as described above are processed for electron microscopy analysis using standard specimen preparation techniques. Briefly, the tissues are cut into
  • Example II The antibodies generated in Example II are appropriately diluted and incubated with the sectioned tissues. After washing, a secondary antibody conjugated with an enzyme such as horseradish peroxidase or an opaque particle such as colloidal gold may be used to detect the primary antibody binding using an electron microscope.
  • an enzyme such as horseradish peroxidase or an opaque particle such as colloidal gold

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps dirigés spécifiquement sur des composants particuliers de la membrane intracellulaire et un procédé d'utilisation de ces anticorps. Un premier aspect de l'invention concerne l'injection de composants membranaires isolés à des souris, de manière à permettre la production d'anticorps spécifiques de ces composants de membrane particuliers. Cette injection peut comprendre un composant membranaire seul ou combiné à un autre composant membranaire, et être associée à une méthode d'immunosuppression. Dans un second aspect de l'invention, ces anticorps sont utilisés en tant que nouveau procédé et nouveau système d'administration de médicaments, ciblés sur des composants particuliers de la membrane intracellulaire. Un troisième aspect concerne l'utilisation de ces anticorps pour l'identification de composants particuliers de la membrane intracellulaire, importants pour les fonctions cellulaires.
PCT/US2001/013852 2000-04-28 2001-04-27 Nouveaux anticorps diriges sur des membranes biologiques Ceased WO2001082901A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/258,977 US20030211111A1 (en) 2001-04-27 2001-04-27 Antibodies to biological membranes
AU2001262960A AU2001262960A1 (en) 2000-04-28 2001-04-27 New antibodies to biological membranes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20059500P 2000-04-28 2000-04-28
US60/200,595 2000-04-28

Publications (1)

Publication Number Publication Date
WO2001082901A1 true WO2001082901A1 (fr) 2001-11-08

Family

ID=22742370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013852 Ceased WO2001082901A1 (fr) 2000-04-28 2001-04-27 Nouveaux anticorps diriges sur des membranes biologiques

Country Status (2)

Country Link
AU (1) AU2001262960A1 (fr)
WO (1) WO2001082901A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2650294A1 (fr) 2009-10-12 2013-10-16 Pharmacyclics, Inc. Inhibiteurs de la tyrosine-kinase Btk
US10668105B2 (en) 2003-10-08 2020-06-02 Vetstem Biopharma, Inc. Methods of preparing and using novel stem cell compositions and kits comprising the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6072036A (en) * 1992-07-17 2000-06-06 Dana-Farber Cancer Institute, Inc. Method of intracellular binding of target molecules
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6072036A (en) * 1992-07-17 2000-06-06 Dana-Farber Cancer Institute, Inc. Method of intracellular binding of target molecules
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10668105B2 (en) 2003-10-08 2020-06-02 Vetstem Biopharma, Inc. Methods of preparing and using novel stem cell compositions and kits comprising the same
EP2650294A1 (fr) 2009-10-12 2013-10-16 Pharmacyclics, Inc. Inhibiteurs de la tyrosine-kinase Btk

Also Published As

Publication number Publication date
AU2001262960A1 (en) 2001-11-12

Similar Documents

Publication Publication Date Title
Orikasa et al. Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody.
Koscec et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture.
US8815244B2 (en) Method for production of antibody using ostrich
JP2589682B2 (ja) ヒト非▲下−▼小細胞肺癌に関するモノクローナル抗体および抗原
WO1995014042A1 (fr) Anticorps monoclonal anti-tyrosinase humaine
JP2001503601A (ja) 前立腺特異的膜抗原の細胞外ドメインに対して特異的なモノクローナル抗体
US8383767B2 (en) Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain
KR100249294B1 (ko) 사람 mdr1 다중약물 내성 유전자 생성물에 대한 단클론성 항체, 및 그것의 사용방법
JP2002509857A (ja) 乾癬の処置のための方法および組成物
KR100943197B1 (ko) 모발성장을 촉진시키는 올리고펩타이드
JPH0742320B2 (ja) 転移性ヒト腫瘍を確認する方法および組成物
JPH09507754A (ja) 哺乳類悪性細胞の選択的メチオニン飢餓方法
EP2048161A1 (fr) Anticorps monoclonal dirige contre le lox-1 soluble
Maňásková et al. Localization of porcine seminal plasma (PSP) proteins in the boar reproductive tract and spermatozoa
US7241731B2 (en) Oligopeptides for promoting hair growth
WO2001082901A1 (fr) Nouveaux anticorps diriges sur des membranes biologiques
JP2004244411A (ja) ガレクチン９含有医薬
JP3595506B2 (ja) シクロスポリンおよびシクロスポリン代謝産物の、特定領域に対する抗体の生産方法
Nastainczyk et al. Isolation and characterization of a monoclonal anti-protein kinase CK2 β-subunit antibody of the IgG class for the direct detection of CK2 β-subunit in tissue cultures of various mammalian species and human tumors
US20030211111A1 (en) Antibodies to biological membranes
Savory et al. 5α-Reductase type 1 is localized to the outer nuclear membrane
JPH10506372A (ja) Ｃａｎｄｉｄａ感染を処置するためのβＧａｌＮａｃ（１−４）βＧａｌ結合体の使用
Minuth et al. Immunocytochemical localization of a renal glycoprotein (gp CD I) synthesized by cultured collecting duct cells
EP0654532B1 (fr) Anticorps monoclonal pour mucoglycoproteine
Yamashita et al. Immunolocalization of aldolase A subunit using monoclonal antibody in rabbit tissues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10258977

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP